The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA575084
Title LIGHT: A Novel Immunotherapy for Primary and Metastatic Prostate Cancer.
Publication Date Sep 2012
Media Count 14p
Personal Author W. M. Kast
Abstract Over-expression of LIGHT has been show in various tumor models to induce tumor regression and tumor immunogencity. However, the models are based on transplanted tumors that express artificial foreign antigens that function as tumor antigens, LIGHT has never been evaluated in prostate cancer, where self-antigens likely exist. We have provided the first evidence that LIGHT- induced T cells are specific for at least one relevant prostate expressed self- antigen, PSCA. We have also demonstrated that LIGHT treatment in prostate cancer has a positive effect on the tumor microenvironment, which suggests a strong likelihood that combination treatment with LIGHT and immunotherapeutic vaccination will have an impact against primary and possibly metastatic prostate cancer. Thus, therapeutic intervention by delivering LIGHT to the tumors may serve the dual purpose of inhibiting immune-suppression mediated by regulatory T cells while simultaneously activating tumor-specific immune responses, which we hope to demonstrate can be boosted by vaccination. This study may potentially provide a practical means of overcoming tumor-mediated immunosuppressive mechanisms in a variety of solid human tumors, including those of the prostate, which would have important implications for patients who are diagnosed at the later stages of disease and currently have no recourse for treatment.
Keywords Immunotherapy
Prostate cancer
T lymphocytes

Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author University of Southern California, Los Angeles.
Document Type Technical report
Title Note Annual rept. 1 Sep 2011-31 Aug 2012.
NTIS Issue Number 1319
Contract Number W81XWH-11-1-0518

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader